Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Immuron Ltd ADR (NQ: IMRN ) 2.640 -0.060 (-2.22%) Streaming Delayed Price Updated: 3:58 PM EDT, Jul 19, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Immuron Ltd ADR < Previous 1 2 Next > Immuron announces record Travelan® sales globally, Australia and USA July 15, 2024 From Immuron Limited Via GlobeNewswire Immuron requests pre-IND meeting for IMM-529 with FDA filing July 02, 2024 From Immuron Limited Via GlobeNewswire Immuron CEO, Steven Lydeamore to present at the Emerging Growth Conference June 05, 2024 From Immuron Limited Via GlobeNewswire Immuron Board Changes May 31, 2024 From Immuron Limited Via GlobeNewswire Immuron CEO Steven Lydeamore to present at Peak Sky High May 31, 2024 From Immuron Limited Via GlobeNewswire Immuron Limited to Present at the Emerging Growth Conference May 07, 2024 From Immuron Limited Via GlobeNewswire Immuron Director Resignation May 03, 2024 From Immuron Limited Via GlobeNewswire Immuron to host Live Virtual Event April 15, 2024 From Immuron Limited Via GlobeNewswire Immuron Travelan® sales continued strong growth April 10, 2024 From Immuron Limited Via GlobeNewswire Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US March 07, 2024 From Immuron Limited Via GlobeNewswire Immuron Presentation Australian Biologics Festival 2024 February 21, 2024 From Immuron Limited Via GlobeNewswire Immuron achieves record Travelan® sales February 13, 2024 From Immuron Limited Via GlobeNewswire Immuron CEO, Steven Lydeamore Investor Webinar Presentation February 08, 2024 From Immuron Limited Via GlobeNewswire Immuron achieves record half yearly Travelan® sales January 16, 2024 From Immuron Limited Via GlobeNewswire Immuron Clinical Trials Update December 22, 2023 From Immuron Limited Via GlobeNewswire Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study December 04, 2023 From Immuron Limited Via GlobeNewswire Immuron CEO, Steven Lydeamore Investor Webinar Presentation November 28, 2023 From Immuron Limited Via GlobeNewswire Immuron CEO Steven Lydeamore Investor Webinar Presentation November 13, 2023 From Immuron Limited Via GlobeNewswire Immuron CEO Steven Lydeamore presented at AusBioInvest October 30, 2023 From Immuron Limited Via GlobeNewswire Immuron Announces Travelan® Clinical Study Cohort 2 commences October 18, 2023 From Immuron Limited Via GlobeNewswire Immuron achieves record quarterly Travelan® sales October 11, 2023 From Immuron Limited Via GlobeNewswire Immuron hails record monthly sales of Travelan September 14, 2023 Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steve Lydeamore speaks with Proactive following news the company has achieved record monthly sales of its over-the-counter gastrointestinal supplement Travelan®.... Via TheNewswire.com Immuron achieves record monthly Travelan® sales September 13, 2023 From Immuron Limited Via GlobeNewswire Immuron CEO, Steven Lydeamore to present at H.C. Wainwright September 11, 2023 From Immuron Limited Via GlobeNewswire Immuron to present at the Military Health System Research Symposium August 14, 2023 From Immuron Limited Via GlobeNewswire Immuron welcomes launch of Travelan on Amazon US July 26, 2023 Immuron Ltd (NASDAQ:IMRN, ASX:IMC) chief commercial officer Flavio Palumbo speaks with Proactive following the news its Travelan product has launched on Amazon US. Via TheNewswire.com Immuron Announces First Patients Enrolled in Travelan® Clinical Study July 25, 2023 From Immuron Limited Via GlobeNewswire Immuron CEO, Steven Lydeamore to present at Bioshares July 24, 2023 From Immuron Limited Via GlobeNewswire Immuron Business Update - Ateria Health launches Juvia™ in Australia July 11, 2023 From Immuron Limited Via GlobeNewswire Immuron FY23 Sales increase 136% on FY22 Sales July 05, 2023 From Immuron Limited Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.